ES2928084T3 - Inhibidores de GDF-8 - Google Patents

Inhibidores de GDF-8 Download PDF

Info

Publication number
ES2928084T3
ES2928084T3 ES16711043T ES16711043T ES2928084T3 ES 2928084 T3 ES2928084 T3 ES 2928084T3 ES 16711043 T ES16711043 T ES 16711043T ES 16711043 T ES16711043 T ES 16711043T ES 2928084 T3 ES2928084 T3 ES 2928084T3
Authority
ES
Spain
Prior art keywords
bipyridin
alkyl
pyridine
imidazo
methyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES16711043T
Other languages
English (en)
Spanish (es)
Inventor
Pingyu Ding
Marina Gelman
Todd Kinsella
Rajinder Singh
Somasekhar Bhamidipati
Upender Velaparthi
Robert Borzilleri
Hasibur Rahaman
Jayakumar Warrier
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bristol Myers Squibb Co
Rigel Pharmaceuticals Inc
Original Assignee
Bristol Myers Squibb Co
Rigel Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co, Rigel Pharmaceuticals Inc filed Critical Bristol Myers Squibb Co
Application granted granted Critical
Publication of ES2928084T3 publication Critical patent/ES2928084T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
    • C07B59/002—Heterocyclic compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C53/00—Saturated compounds having only one carboxyl group bound to an acyclic carbon atom or hydrogen
    • C07C53/02—Formic acid
    • C07C53/06—Salts thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C53/00—Saturated compounds having only one carboxyl group bound to an acyclic carbon atom or hydrogen
    • C07C53/15—Saturated compounds having only one carboxyl group bound to an acyclic carbon atom or hydrogen containing halogen
    • C07C53/16—Halogenated acetic acids
    • C07C53/18—Halogenated acetic acids containing fluorine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/05—Isotopically modified compounds, e.g. labelled

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Diabetes (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurology (AREA)
  • Immunology (AREA)
  • Emergency Medicine (AREA)
  • Rheumatology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
ES16711043T 2015-02-20 2016-02-15 Inhibidores de GDF-8 Active ES2928084T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562119052P 2015-02-20 2015-02-20
PCT/US2016/017938 WO2016133838A1 (en) 2015-02-20 2016-02-15 Gdf-8 inhibitors

Publications (1)

Publication Number Publication Date
ES2928084T3 true ES2928084T3 (es) 2022-11-15

Family

ID=55587333

Family Applications (1)

Application Number Title Priority Date Filing Date
ES16711043T Active ES2928084T3 (es) 2015-02-20 2016-02-15 Inhibidores de GDF-8

Country Status (8)

Country Link
US (1) US9981944B2 (enExample)
EP (1) EP3259264B1 (enExample)
JP (1) JP6800158B2 (enExample)
CN (1) CN107531666A (enExample)
AR (1) AR103740A1 (enExample)
ES (1) ES2928084T3 (enExample)
TW (1) TW201643157A (enExample)
WO (1) WO2016133838A1 (enExample)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK3636649T3 (da) 2014-01-24 2024-05-21 Turning Point Therapeutics Inc Diarylmakrocykler som modulatorer af proteinkinaser
EP3317285B1 (en) 2015-07-02 2021-01-27 Turning Point Therapeutics, Inc. Chiral diaryl macrocycles as modulators of protein kinases
EP3319968A1 (en) 2015-07-06 2018-05-16 Rodin Therapeutics, Inc. Heterobicyclic n-aminophenyl-amides as inhibitors of histone deacetylase
WO2017007759A1 (en) 2015-07-06 2017-01-12 Tp Therapeutics, Inc. Diaryl macrocycle polymorph
RS62639B1 (sr) 2015-07-06 2021-12-31 Alkermes Inc Hetero-halo inhibitori histonskih deacetilaza
HK1255330A1 (zh) 2015-08-26 2019-08-16 缆图药品公司 适用於治疗与ntrk相关的病症的化合物和组合物
WO2017087778A1 (en) 2015-11-19 2017-05-26 Blueprint Medicines Corporation Compounds and compositions useful for treating disorders related to ntrk
AU2018207402B2 (en) 2017-01-11 2023-09-28 Alkermes, Inc. Bicyclic inhibitors of histone deacetylase
EA039417B1 (ru) 2017-08-07 2022-01-25 Родин Терапеутикс, Инк. Бициклические ингибиторы гистондеацетилазы
BR112020003481B1 (pt) 2017-08-22 2023-12-05 Bayer Aktiengesellschaft Derivados de heterocicleno, seus usos, formulação agroquímica, e métodos para controlar pragas animais e para proteger sementes ou uma planta germinativa de pragas
CN110066276B (zh) * 2018-01-24 2020-09-18 上海璎黎药业有限公司 芳香杂环化合物、其中间体、制备方法、药物组合物和应用
US11414431B2 (en) * 2018-10-15 2022-08-16 Nimbus Lakshmi, Inc. Substituted pyrazolo[1,5-a]pyrimidines as TYK2 inhibitors
AR119140A1 (es) 2019-06-13 2021-11-24 Pi Industries Ltd Compuestos heterocíclicos fusionados y su uso como agentes de control de plagas

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE322681T1 (de) 1999-01-21 2006-04-15 Metamorphix Inc Inhibitoren für wachstumdifferenzierungsfaktor und ihre anwendungen
JP2001097950A (ja) * 1999-10-01 2001-04-10 Sankio Chemical Co Ltd 新規なピリジン誘導体
US7320789B2 (en) 2001-09-26 2008-01-22 Wyeth Antibody inhibitors of GDF-8 and uses thereof
MXPA06007017A (es) 2003-12-18 2006-08-31 Janssen Pharmaceutica Nv Derivados de pirido y pirimidopirimidina como agentes antiproliferativos.
PE20091268A1 (es) 2007-12-19 2009-09-19 Amgen Inc Derivados heterociclicos como inhibidores de pi3 quinasa
FR2925902B1 (fr) 2008-01-02 2011-01-07 Sanofi Aventis DERIVES D'IMIDAZO°1,2-a!PYRIDINE-2-CARBOXAMIDES, LEUR PREPARATION ET LEUR APPLICATION EN THERAPEUTIQUE
EP2304834A4 (en) 2008-07-18 2014-03-19 Flexel Llc THIN, FLEXIBLE AND RECHARGEABLE ELECTROCHEMICAL ENERGY CELL AND METHOD FOR THE PRODUCTION THEREOF
WO2011050245A1 (en) 2009-10-23 2011-04-28 Yangbo Feng Bicyclic heteroaryls as kinase inhibitors
US8575203B2 (en) 2010-04-21 2013-11-05 Boehringer Ingelheim International Gmbh Chemical compounds
WO2011141848A1 (en) 2010-05-11 2011-11-17 Pfizer Inc. Morpholine compounds as mineralocorticoid receptor antagonists
KR20130131293A (ko) * 2010-07-05 2013-12-03 메르크 파텐트 게엠베하 키나아제 - 유도된 질환의 치료에 유용한 바이피리딜 유도체
CA2852936A1 (en) 2011-10-20 2013-04-25 Glaxosmithkline Llc Substituted bicyclic aza-heterocycles and analogues as sirtuin modulators
EP2773641B1 (en) 2011-10-31 2017-09-27 Xenon Pharmaceuticals Inc. Biaryl ether sulfonamides and their use as therapeutic agents
BR112014027181A2 (pt) 2012-05-15 2017-06-27 Novartis Ag derivados de benzamida para a inibição da atividade de abl1, abl2 e bcr-abl1
EP2903978B1 (en) 2012-10-05 2022-12-07 Rigel Pharmaceuticals, Inc. Gdf-8 inhibitors
WO2014074657A1 (en) 2012-11-08 2014-05-15 Bristol-Myers Squibb Company Bicyclic heterocycle substituted pyridyl compounds useful as kinase modulators
US9908867B2 (en) 2013-01-08 2018-03-06 Samumed, Llc 3-(benzoimidazol-2-yl)-indazole inhibitors of the Wnt signaling pathway and therapeutic uses thereof
US20160280699A1 (en) 2013-09-26 2016-09-29 Bayer Pharma Aktiengesellschaft Substituted phenylalanine derivatives
RS58376B1 (sr) 2013-10-11 2019-04-30 Hoffmann La Roche Supstituisana heterociklična sulfonamidna jedinjenja korisna kao modulatori trpa1
GB201321729D0 (en) 2013-12-09 2014-01-22 Ucb Pharma Sa Therapeutic agents
CN106536507B (zh) * 2014-04-08 2020-04-07 里格尔药品股份有限公司 作为TGF-β抑制剂的2,3-二取代的吡啶化合物及其使用方法

Also Published As

Publication number Publication date
CN107531666A (zh) 2018-01-02
EP3259264A1 (en) 2017-12-27
US20160264553A1 (en) 2016-09-15
JP2018505903A (ja) 2018-03-01
US9981944B2 (en) 2018-05-29
WO2016133838A1 (en) 2016-08-25
TW201643157A (zh) 2016-12-16
AR103740A1 (es) 2017-05-31
JP6800158B2 (ja) 2020-12-16
EP3259264B1 (en) 2022-07-27

Similar Documents

Publication Publication Date Title
ES2928084T3 (es) Inhibidores de GDF-8
ES2789331T3 (es) Inhibidores de TGF-beta
KR102793183B1 (ko) 헤테로시클릭 rip1 키나제 억제제
EP3283479B1 (en) Tgf-beta inhibitors
ES2759240T3 (es) Compuestos de piridina 2,3-disustituidos como inhibidores de TGF-beta
ES2895626T3 (es) Derivados de imidazol condensados como inhibidores de TGF-beta
ES2918924T3 (es) Inhibidores de TGF-beta
ES2813875T3 (es) Compuestos y procedimientos de uso
TW202144345A (zh) Ｋｒａｓ突變蛋白抑制劑
CN103012399B (zh) 7-氧代吡啶并嘧啶类化合物及其药用组合物和应用
JP2018150319A (ja) キナーゼ阻害剤としてのビアリールアミド化合物
KR20230090318A (ko) 헬리오스의 피페리디닐 소분자 분해 및 사용 방법들
AU2017208555B2 (en) New 6-membered heteroaromatic substituted cyanoindoline derivatives as NIK inhibitors
CN105732614B (zh) 磺酰胺基芳基炔类化合物及其用途
ES2844211T3 (es) Compuestos y composiciones en calidad de inhibidores de quinasa
TW201838981A (zh) 嘧啶基-吡啶氧基-萘基化合物以及治療ire1相關之疾病及病症的方法
KR20150090044A (ko) 아자퀴나졸린 카복사미드 유도체
WO2019189555A1 (ja) 複素環化合物
CN110156782B (zh) 作为pi3k/mtor抑制剂的吡啶基取代的稠合喹啉化合物
EP3810596B1 (en) Quinoline derivatives useful as tyrosine kinase inhibitors
TW202039425A (zh) 雙取代炔類衍生物、包含其之藥物組成及組、及用於製備其之製程
CN115772167A (zh) 含脲结构的化合物及其应用
HK40001081A (en) Substituted 2, 4-diamino-quinoline derivatives for use in the treatment of proliferative diseases
HK1244785B (en) Tgf-beta inhibitors